Allogene Therapeutics
Todd Sisitsky is the Managing Partner of the TPG Capital business in the U.S. and EU, and co-leads the firm’s investment activities in the healthcare services and pharmaceutical/medical device sectors. Prior to joining TPG in 2003, Todd worked at Forstmann Little & Company and Oak Hill Capital Partners. He received an M.B.A. from the Stanford Graduate School of Business, where he was an Arjay Miller Scholar, and earned his undergraduate degree from Dartmouth College, where he graduated summa cum laude. He has played leadership roles on TPG’s investments in Aptalis, Biomet, Fenwal, Healthscope, IASIS Healthcare, Immucor, IMS Health, Par Pharmaceutical and Surgical Care Affiliates. Todd serves on the Board of Directors for the Campaign for Tobacco-Free Kids and the Dartmouth Medical School Board of Overseers.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.